Search | IOVS | ARVO Journals

Showing 1 – 20 of 56

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina December 2024

Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies

PDF

Melissa A. Calton; Roxanne H. Croze; Christian Burns; Ghezal Beliakoff; Tandis Vazin; Paul Szymanski; Christopher Schmitt; Austin Klein; Meredith Leong; Melissa Quezada; Jenny Holt; Gabe Bolender; Katherine Barglow; Devi Khoday; Thomas Mason; Katherine Delaria; Mohammad Hassanipour; Melissa Kotterman; Arshad M. Khanani; David Schaffer; Peter Francis; David Kirn
TAGS: eye, gene therapy, genetics, retinal diseases, transgenes, spatial vectors, choroidal neovascularization, capsid, primates, disease vectors
Invest. Ophthalmol. Vis. Sci.. 2024; 65(14):1. https://doi.org/10.1167/iovs.65.14.1

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2024

Assessment of pre-existing anti-drug antibodies (ADAs) in pooled serum against novel trispecific biologic RO-104 analogs

Isabel Ray; Alina K Sinha; Li Xu; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):715.

ARVO Annual Meeting Abstract June 2024

Rat Laser CNV Efficacy Studies with the Novel Trispecific Protein RO-104

Alina K Sinha; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2163.

ARVO Annual Meeting Abstract June 2024

Inhibition of VEGFA induced HUVEC migration via RO-104, a novel trispecific protein

Yixuan Ma; Alina K Sinha; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Ashwin Gupta; Nikhil Gupta; Megana Paidela; Isabel Ray; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1942.

ARVO Annual Meeting Abstract June 2024

Interim results from the PRISM randomized phase 2 dose expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration

Arshad M. Khanani; Allen Hu; David Aaron Eichenbaum; Raj K Maturi; Veeral S Sheth; Albert O Edwards; Sunil Gupta; Joel Pearlman; Suhail Alam; Jeffrey S Heier; Fuad Makkouk; Andres Emanuelli; Dante Pieramici; John A Wells; Chyong Nien; Robert Kim

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4356.

ARVO Annual Meeting Abstract June 2024

Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial

Varun Malhotra; Michael A. Klufas; Dennis M Marcus; Jordan M Graff; Peter A Campochiaro; Salman Rahman; Paul Latkany; Shamika Gune; Stephanie DeGraaf; Ashwini Bobbala; Mel Rabena; Carlos Ruiz; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6233.

ARVO Annual Meeting Abstract June 2024

The EC50 binding characteristics of novel trispecific protein, RO-104

Parth Patel; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Alina K Sinha; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Jessi Prentice; Ramanath Bhandari; Ramesh Bhatt

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5088.

ARVO Annual Meeting Abstract June 2024

Binding characteristics of a novel trispecific protein RO-104 to aflibercept

Megana Paidela; Li Xu; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Alina K Sinha; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1950.

ARVO Annual Meeting Abstract June 2024

Greater reduction in pigment epithelial detachment size in TENAYA/LUCERNE with faricimab 6.0 mg vs aflibercept 2.0 mg during head-to-head dosing in patients with nAMD

Nikolas London; Arshad M. Khanani; Timothy Y Y Lai; Jennifer I Lim; Aachal Kotecha; Philippe Margaron; Shriji Patel; Audrey Souverain; Jeffrey R Willis; Ming Yang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5690.

ARVO Annual Meeting Abstract June 2024

Characterization of the Receptor-Ligand Competition of RO-104 IC50 Potencies

Ashwin Gupta; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Ramesh Bhatt; Parth Patel; Alina K Sinha; Nikhil Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):264.

ARVO Annual Meeting Abstract June 2024

Pharmacokinetic Analysis of RO-104 in Rabbit Eye Vitreous

Nikhil Gupta; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Ashwin Gupta; Alina K Sinha; Megana Paidela; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):263.

ARVO Annual Meeting Abstract June 2024

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study - 2 Year Results

Aamir Abdul Aziz; Hannah Khan; Mark Rami Barakat; Ramanath Bhandari; Emmanuel Chang; Giulia Corradetti; Carl J Danzig; Jordan M Graff; Nikolas JS London; Jared Nielsen; Veeral Sheth; Jeremy Wolfe; Robert William Wong; SriniVas R Sadda; Michael Andrew Singer; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2789.

ARVO Annual Meeting Abstract June 2024

The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration

David Aaron Eichenbaum; Vrinda Hershberger; Sunil S Patel; Ashkan Michael Abbey; W Zachery Bridges; Arshad M. Khanani; Stephanie Ruggiero; Monica Roy; Jay S Duker; Dario A Paggiarino

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4401.

ARVO Annual Meeting Abstract June 2024

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Greggory Gahn; Peter K Kaiser; Arshad M. Khanani; Carl J Danzig; Jeffrey S Heier; Julie Clark; Liansheng Zhu; Hersh Patel; Don Luo; Nikhil Patel; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4400.

ARVO Annual Meeting Abstract June 2024

Real-World Efficacy and Safety of the Ranibizumab Port-Delivery System in Neovascular AMD: The SUMMIT Study

Humza Sulahria; Hannah Khan; Aamir Abdul Aziz; Huma Khan; Veeral Sheth; Jordan M Graff; David Aaron Eichenbaum; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5703.

ARVO Annual Meeting Abstract June 2024

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

Ohidul Mojumder; Aamir Abdul Aziz; Hannah Khan; Ashkan Michael Abbey; Robert L Avery; Himanshu K Banda; Mark Rami Barakat; Ramanath Bhandari; Emmanuel Chang; Sara Haug; Nikolas London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5675.

ARVO Annual Meeting Abstract June 2024

The Real-World Efficacy and Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study

Huma Khan; Hannah Khan; Aamir A Aziz; Greggory Gahn; Mark Rami Barakat; Giulia Corradetti; Carl J Danzig; Jordan M Graff; Jared Nielsen; Jeremy Wolfe; SriniVas R Sadda; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6259.

ARVO Annual Meeting Abstract June 2023

The Characterization of the Ang-2 Arm of a Novel Anti-VEGF-A and Ang-2 Bispecific Protein (RO-101) in Comparison to Faricimab-svoa

Megana Paidela; Li Xu; Parth Patel; John Mitchell Kunzeman; Jessi Prentice; Robert Lowenthal; Mark Barakat; Arshad M. Khanani; Peter K Kaiser; Jeffrey L. Olson; Jeffrey S Heier; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):739.

ARVO Annual Meeting Abstract June 2023

Binding Characteristics of the VEGF Arm of a Novel Bispecific Protein RO-101 in Comparison to Faricimab-svoa

Parth Patel; Li Xu; Megana Paidela; John Mitchell Kunzeman; Jessi Prentice; Mark Barakat; Robert Lowenthal; Arshad M. Khanani; Peter M Kaiser; Jeffrey S Heier; Jeffrey L. Olson; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):738.

ARVO Annual Meeting Abstract June 2023

Interim results for the Phase 1/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration

Arshad M. Khanani; Vrinda S Hershberger; Christine Nichols Kay; Allen Hu; David Aaron Eichenbaum; Glenn J Jaffe; Carol Chung; Somayeh Honarmand; Chyong Nien; Schonmei Lee; Harsha Kabra; David Kirn; Robert Kim

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5055.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies

Assessment of pre-existing anti-drug antibodies (ADAs) in pooled serum against novel trispecific biologic RO-104 analogs

Rat Laser CNV Efficacy Studies with the Novel Trispecific Protein RO-104

Inhibition of VEGFA induced HUVEC migration via RO-104, a novel trispecific protein

Interim results from the PRISM randomized phase 2 dose expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration

Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial

The EC50 binding characteristics of novel trispecific protein, RO-104

Binding characteristics of a novel trispecific protein RO-104 to aflibercept

Greater reduction in pigment epithelial detachment size in TENAYA/LUCERNE with faricimab 6.0 mg vs aflibercept 2.0 mg during head-to-head dosing in patients with nAMD

Characterization of the Receptor-Ligand Competition of RO-104 IC50 Potencies

Pharmacokinetic Analysis of RO-104 in Rabbit Eye Vitreous

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study - 2 Year Results

The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Real-World Efficacy and Safety of the Ranibizumab Port-Delivery System in Neovascular AMD: The SUMMIT Study

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

The Real-World Efficacy and Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study

The Characterization of the Ang-2 Arm of a Novel Anti-VEGF-A and Ang-2 Bispecific Protein (RO-101) in Comparison to Faricimab-svoa

Binding Characteristics of the VEGF Arm of a Novel Bispecific Protein RO-101 in Comparison to Faricimab-svoa

Interim results for the Phase 1/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration

To View More...

You must be signed into an individual account to use this feature.